11/20/2019  5:30:45 PM Chg. +1.160 Volume Bid8:01:29 AM Ask7:46:12 AM Market Capitalization Dividend Y. P/E Ratio
25.400CHF +4.79% 701,796
Turnover: 15.25 mill.
25.300Bid Size: 2,200 25.400Ask Size: 818 2.89 bill.CHF 0.00% -

Business description

Idorsia Ltd is an independent biopharmaceutical company specialized in the discovery and development of small molecule therapeutics to meet significant unmet medical needs. Idorsia has a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. Idorsia directly benefits from Actelion’s 19-year history and experience, inheriting Actelion’s established and validated drug discovery engine and a strong cross-section of its development organization. Idorsia’s pipeline will be developed by its own development organization. Headquartered in Allschwil, Switzerland, Idorsia was incorporated on 2 March 2017 and was launched on 16 June 2017.
 

Management board & Supervisory board

CEO
Jean-Paul Clozel
Management board
André C. Muller, Guy Braunstein, Martine Clozel, Simon Jose
Supervisory board
Jean-Paul Clozel, Jean-Pierre Garnier, John J. Greisch, Mathieu Simon, Robert J. Bertolini, Viviane Monges
 

Company data

Name: Idorsia Ltd
Address: Hegenheimermattweg 91,CH-4123 Allschwil
Phone: +41-58-8440000
Fax: -
E-mail: info@idorsia.com
Internet: https://www.idorsia.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: -
IPO date: 6/16/2017

Investor relations

Name: Andrew C. Weiss
IR phone: +41-58-8441010
IR Fax: -
IR e-mail: investor.relations@idorsia.com

Company calendar

CW 6 | 2/6/2020 4th Quarter/Annual Report
CW 17 | 4/23/2020 Interim Report 1st Quarter/3 Months
 

Main Shareholders

Freefloat
 
54.21%
Jean-Paul Clozel und Martine Clozel
 
25.95%
Johnson & Johnson
 
9.90%
Rudolf Maag
 
7.23%
John Paulson
 
2.71%